Lower T cell levels within the NSD1 subtype are particularly clinically interesting, as T cell levels (particularly CD8+ T cells) represent markers of anti-cancer immune response that are associated with favorable prognosis in HNSC and other solid cancers42,57–62. This evidence concerns the gene CD8A and cancer.